Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
18
ADCT Quote, Financials, Valuation and Earnings
Last price:
$3.30
Seasonality move
:
8.56%
Day range:
$3.25 - $3.60
52-week range:
$1.05 - $4.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.06x
P/B ratio:
--
Volume:
1.8M
Avg. volume:
1.2M
1-year change:
71.35%
Market cap:
$407.6M
Revenue:
$70.8M
EPS (TTM):
-$1.45
Analysts' Opinion
-
Consensus RatingADC Therapeutics SA has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.00, ADC Therapeutics SA has an estimated upside of 143.16% from its current price of $3.29.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $3.29.
Fair Value
-
According to the consensus of 5 analysts, ADC Therapeutics SA has 143.16% upside to fair value with a price target of $8.00 per share.
ADCT vs. S&P 500
-
Over the past 5 trading days, ADC Therapeutics SA has underperformed the S&P 500 by -23.73% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ADC Therapeutics SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ADC Therapeutics SA revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter ADC Therapeutics SA reported revenues of $16.4M.
Earnings Growth
-
ADC Therapeutics SA has grown year-over-year earnings for 1 quarter straight. In the most recent quarter ADC Therapeutics SA reported earnings per share of -$0.30.
Enterprise value:
630.3M
EV / Invested capital:
2.87x
Price / LTM sales:
5.06x
EV / EBIT:
--
EV / Revenue:
8.38x
PEG ratio (5yr expected):
-0.07x
EV / Free cash flow:
-4.61x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$67.2M
Return On Assets:
-53.68%
Net Income Margin (TTM):
-221.97%
Return On Equity:
--
Return On Invested Capital:
-148.42%
Operating Margin:
-186.23%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $122.6M | $70.7M | $75.2M | $18.5M | $16.4M | |
| Gross Profit | $119.3M | $62.4M | $67.2M | $16.8M | $15.1M | |
| Operating Income | -$134.3M | -$136.6M | -$122.5M | -$35.6M | -$30.6M | |
| EBITDA | -$131.2M | -$133.3M | -$120M | -$34.8M | -$30.5M | |
| Diluted EPS | -$2.19 | -$2.40 | -$1.45 | -$0.42 | -$0.30 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $568.4M | $438.1M | $375.6M | $333M | $287.1M | |
| Total Assets | $638M | $531.8M | $466.9M | $349.1M | $289.8M | |
| Current Liabilities | $59.3M | $87.6M | $78.2M | $67.7M | $62M | |
| Total Liabilities | $450.7M | $427M | $521.1M | $521M | $527.9M | |
| Total Equity | $187.3M | $104.8M | -$54.2M | -$171.9M | -$238.2M | |
| Total Debt | $157.2M | $104.2M | $109.2M | $123.1M | $456.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$143.1M | -$134.6M | -$136.4M | -$27.9M | -$31.7M | |
| Cash From Investing | -$1.3M | -$1.1M | -$358.4K | -$237.5K | -$1.9K | |
| Cash From Financing | $73M | $98.9M | $96.3M | $2.3M | $455.3K | |
| Free Cash Flow | -$144.6M | -$135.7M | -$136.7M | -$28.2M | -$31.7M | |
ADCT
Sector
Market Cap
$407.6M
$28.5M
Price % of 52-Week High
68.54%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-36.48%
-1.33%
1-Year Price Total Return
71.35%
-20.32%
Beta (5-Year)
1.887
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.08
200-day SMA
Buy
Level
$2.87
Bollinger Bands (100)
Sell
Level
3.08 - 4.22
Chaikin Money Flow
Sell
Level
-1.9M
20-day SMA
Sell
Level
$4.06
Relative Strength Index (RSI14)
Sell
Level
33.23
ADX Line
Sell
Level
23.57
Williams %R
Neutral
Level
-79.1667
50-day SMA
Sell
Level
$4.16
MACD (12, 26)
Sell
Level
-0.08
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Sell
Level
-124K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.5414)
Sell
CA Score
(Annual)
Level (-6.8003)
Buy
Beneish M-Score
(Annual)
Level (-2.834)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (8.8597)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Stock Forecast FAQ
In the current month, ADCT has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ADCT average analyst price target in the past 3 months is $8.00.
-
Where Will ADC Therapeutics SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that ADC Therapeutics SA share price will rise to $8.00 per share over the next 12 months.
-
What Do Analysts Say About ADC Therapeutics SA?
Analysts are divided on their view about ADC Therapeutics SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ADC Therapeutics SA is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is ADC Therapeutics SA's Price Target?
The price target for ADC Therapeutics SA over the next 1-year time period is forecast to be $8.00 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ADCT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ADC Therapeutics SA is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ADCT?
You can purchase shares of ADC Therapeutics SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ADC Therapeutics SA shares.
-
What Is The ADC Therapeutics SA Share Price Today?
ADC Therapeutics SA was last trading at $3.30 per share. This represents the most recent stock quote for ADC Therapeutics SA. Yesterday, ADC Therapeutics SA closed at $3.29 per share.
-
How To Buy ADC Therapeutics SA Stock Online?
In order to purchase ADC Therapeutics SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ADCT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ADCT
Sector
P/E ratio
--
23.75x
PEG ratio
-0.07x
-0.01x
P/B ratio
--
1.83x
Price / LTM sales
5.06x
1.60x
Growth Metrics
ADCT
Sector
Revenue growth
-11.03%
4.85%
Earnings growth
28.44%
11.11%
Revenue (5-year growth)
97.79%
6.45%
Earnings forecast
--
-$0.20
Profitability
ADCT
Sector
Profitability FY 2024
$61.6M
$3.6M
Return on invested capital
-148.42%
-30.98%
Return on assets
-53.68%
-27.62%
Return on equity
--
-36.69%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Apr
2
Estimated Next Earnings Date
Feb
9
Balance Sheet
ADCT
Sector
Total cash
$234.7M
$27.2M
Short term investments
--
$25.7M
Total assets
$322M
$79.7M
Long term debt
$456.5M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 48.08% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 6.66% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 6.48% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
